tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

ZVRA Stock Latest News

Zevra Therapeutics price target raised to $29 from $25 at Cantor Fitzgerald
The FlyZevra Therapeutics price target raised to $29 from $25 at Cantor Fitzgerald
14h ago
ZVRA
Zevra Therapeutics initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Zevra Therapeutics initiated with a Buy at H.C. Wainwright
9d ago
ZVRA
Zevra Therapeutics Elects New Directors at Annual Meeting
PremiumCompany Announcements
Zevra Therapeutics Elects New Directors at Annual Meeting
1M ago
8K
ZVRA
Zevra announces 3 proxy advisory firms recommended vote ‘FOR’ Dixon, Favorito
PremiumThe Fly
Zevra announces 3 proxy advisory firms recommended vote ‘FOR’ Dixon, Favorito
2M ago
ZVRA
Zevra Therapeutics Shines in Earnings Call with MIPLYFFA Success
PremiumCompany Announcements
Zevra Therapeutics Shines in Earnings Call with MIPLYFFA Success
2M ago
ZVRA
Zevra Therapeutics: Strong Financial Performance and Strategic Initiatives Drive Buy Rating
PremiumRatingsZevra Therapeutics: Strong Financial Performance and Strategic Initiatives Drive Buy Rating
2M ago
ZVRA
Zevra Therapeutics: Strong Sales and Strategic Initiatives Drive Buy Rating
Premium
Ratings
Zevra Therapeutics: Strong Sales and Strategic Initiatives Drive Buy Rating
2M ago
ZVRA
Promising Outlook for Zevra Therapeutics: Buy Rating Driven by Strong Miplyffa Launch and Robust Financial Performance
Premium
Ratings
Promising Outlook for Zevra Therapeutics: Buy Rating Driven by Strong Miplyffa Launch and Robust Financial Performance
2M ago
ZVRA
Zevra Therapeutics price target raised to $19 from $18 at Citizens JMP
PremiumThe Fly
Zevra Therapeutics price target raised to $19 from $18 at Citizens JMP
2M ago
ZVRA
Zevra Therapeutics Reports Strong Q1 2025 Results
PremiumCompany Announcements
Zevra Therapeutics Reports Strong Q1 2025 Results
2M ago
ZVRA
Zevra Therapeutics reports Q1 EPS (6c), consensus (18c)
PremiumThe Fly
Zevra Therapeutics reports Q1 EPS (6c), consensus (18c)
2M ago
ZVRA
ZVRA Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
ZVRA Upcoming Earnings Report: What to Expect?
2M ago
ZVRA
Zevra Therapeutics urges stockholders to vote for director nominees
PremiumThe FlyZevra Therapeutics urges stockholders to vote for director nominees
3M ago
ZVRA
Zevra Therapeutics announces publication on arimoclomol
Premium
The Fly
Zevra Therapeutics announces publication on arimoclomol
3M ago
ZVRA
Zevra Therapeutics closes sale of Rare Disease PRV for $150M
Premium
The Fly
Zevra Therapeutics closes sale of Rare Disease PRV for $150M
3M ago
ZVRA
Zevra Therapeutics management to meet with Cantor Fitzgerald
PremiumThe Fly
Zevra Therapeutics management to meet with Cantor Fitzgerald
4M ago
ZVRA
Optimistic Buy Rating for Zevra Therapeutics Driven by Miplyffa Launch and Strategic Financial Moves
PremiumRatings
Optimistic Buy Rating for Zevra Therapeutics Driven by Miplyffa Launch and Strategic Financial Moves
4M ago
ZVRA
Zevra Therapeutics price target raised to $22 from $20 at Guggenheim
PremiumThe Fly
Zevra Therapeutics price target raised to $22 from $20 at Guggenheim
4M ago
ZVRA
Zevra Therapeutics: Promising Outlook with Strong Financials and Strategic Focus on Rare Diseases
PremiumRatings
Zevra Therapeutics: Promising Outlook with Strong Financials and Strategic Focus on Rare Diseases
4M ago
ZVRA
Zevra Therapeutics price target raised to $25 from $23 at Canaccord
PremiumThe FlyZevra Therapeutics price target raised to $25 from $23 at Canaccord
4M ago
ZVRA
Zevra Therapeutics: Strong Buy Rating Backed by Impressive Sales and Robust Financial Position
Premium
Ratings
Zevra Therapeutics: Strong Buy Rating Backed by Impressive Sales and Robust Financial Position
4M ago
ZVRA
Zevra Therapeutics’ Earnings Call Highlights Success and Growth
Premium
Company Announcements
Zevra Therapeutics’ Earnings Call Highlights Success and Growth
4M ago
ZVRA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >